AiCuris adenovirus program

The AiCuris adenovirus program is a preclinical-stage antiviral research initiative focused on developing treatments for adenovirus infections in immunocompromised populations. This includes patients undergoing solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT), who are at high risk for severe, disseminated adenovirus disease. Adenoviruses can cause significant morbidity and mortality in these vulnerable groups, potentially leading to pneumonia, hepatitis, and hemorrhagic cystitis. While the specific molecular target and modality of the lead candidate remain undisclosed, the program aims to address a critical gap in the clinical management of transplant-associated viral infections, where current therapeutic options are often limited by significant toxicity or insufficient efficacy.

Other names

Adenovirus programAicuris Anti-infective Cures-adenovirus-adenovirus infections in immunocompromised patients (solid organ and stem cell transplant)